UY25790A1 - Formas farmaceuticas de eritropoyetina humana recombinante estables a temperatura ambiente y apropiadas para su uso en humanos, formulaciones y procedimientos de liofilizacion para su obtencion. - Google Patents

Formas farmaceuticas de eritropoyetina humana recombinante estables a temperatura ambiente y apropiadas para su uso en humanos, formulaciones y procedimientos de liofilizacion para su obtencion.

Info

Publication number
UY25790A1
UY25790A1 UY25790A UY25790A UY25790A1 UY 25790 A1 UY25790 A1 UY 25790A1 UY 25790 A UY25790 A UY 25790A UY 25790 A UY25790 A UY 25790A UY 25790 A1 UY25790 A1 UY 25790A1
Authority
UY
Uruguay
Prior art keywords
recombinant human
humans
stable
room temperature
formulations
Prior art date
Application number
UY25790A
Other languages
English (en)
Inventor
Vidal Alejandro
Melo Carlos
Criscuolo Marcelo
Carcagno Miguel
Original Assignee
Bio Sidus S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Sidus S A filed Critical Bio Sidus S A
Publication of UY25790A1 publication Critical patent/UY25790A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La peresente invención se refiere a formas farmacéuticas de Eritropoyetina (EPO) Humana Recombinante que se caracterizan porque: a) son estables a temperatura ambiente, b) son liofilizadas, c) son apropiadas para su uso en humanos y d) contienen un sacárido, NaCl, NaH2PO4, NaHPO4.12 H2O, albúmina humana, Eritropoyetina Humana Recombinante y agua. La EPO es una proteína que ha demostrado gran eficacia para el tratamiento de anemias. Las formulaciones reivindicadas contienen 1000 UI, 2000 UI, 4000 UI y 10000 UI de EPO con el agregado de excipientes específicos que aseguran la isotonicidad y estabilidad del producto.
UY25790A 1998-11-06 1999-11-05 Formas farmaceuticas de eritropoyetina humana recombinante estables a temperatura ambiente y apropiadas para su uso en humanos, formulaciones y procedimientos de liofilizacion para su obtencion. UY25790A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AR9805608 1998-11-06
AR9900677 1999-02-23

Publications (1)

Publication Number Publication Date
UY25790A1 true UY25790A1 (es) 2000-08-21

Family

ID=25590825

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25790A UY25790A1 (es) 1998-11-06 1999-11-05 Formas farmaceuticas de eritropoyetina humana recombinante estables a temperatura ambiente y apropiadas para su uso en humanos, formulaciones y procedimientos de liofilizacion para su obtencion.

Country Status (3)

Country Link
AU (1) AU1520800A (es)
UY (1) UY25790A1 (es)
WO (1) WO2000027419A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9905868A (pt) 1998-11-06 2001-01-23 Bio Sidus S A Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento
US6777205B1 (en) 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
BR9917606A (pt) 1998-11-06 2002-12-31 Bio Sidus S A Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
DK1311285T4 (en) 2000-05-15 2017-07-24 Hoffmann La Roche Liquid pharmaceutical composition containing an erythropoietin derivative
US7772182B2 (en) 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
CN108606955B (zh) * 2016-12-09 2021-10-26 江苏豪森药业集团有限公司 培化西海马肽的药用组合物及其制备方法
WO2024064887A2 (en) * 2022-09-23 2024-03-28 Cal Poly Corporation Development of solid-state storage of complex biochemical systems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
SE9300105D0 (sv) * 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
US5876992A (en) * 1996-07-03 1999-03-02 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes

Also Published As

Publication number Publication date
AU1520800A (en) 2000-05-29
WO2000027419A1 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
HRP20020880B1 (en) New pharmaceutical composition
BR9201015A (pt) Conjugado de proteina,composto,processo para preparar o conjugado,composicoes farmaceuticas e uso
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
ATE206308T1 (de) Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
DE69129248D1 (de) Peptide mit Endothelin antagonistischer Aktivität, deren Herstellung und pharmazeutische Zusammensetzungen
EA200100097A1 (ru) Составы для борьбы с человеческими вшами
MX9102353A (es) N,o-sulfados de heparosanos, su procedimiento de preparacion y las composiciones farmaceuticas que contienen.
DK0996409T3 (da) Præparat til at forsinke hårvækst og tilsvarende anvendelse
MX18106A (es) Compuesto amidinicos y composiciones usadas para el tratamiento de pneumonia por pneumocystis carinii y otras enfermedades.
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
ATE319729T1 (de) 9a-azalide mit entzündungshemmender wirkung
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
UY25790A1 (es) Formas farmaceuticas de eritropoyetina humana recombinante estables a temperatura ambiente y apropiadas para su uso en humanos, formulaciones y procedimientos de liofilizacion para su obtencion.
RU94041224A (ru) Пептиды с органозащитной активностью, фармацевтическая композиция на их основе и их применение в терапии
ES2177625T3 (es) Citoquina cc-1 humana circulante.
ITRM930291A0 (it) Procedimento per la preparazione di biopolimeri iodurati con attivita'disinfettante e cicatrizzante, e biopolimeri iodurati cosi' ottenuti.
TR200100637T2 (tr) Yeni doğal ürün türevleri
ES2181592B1 (es) Uso de glicoproteina para el tratamiento y re-epitelizacion de heridas
ES2038606T3 (es) Una composicion para la preparacion extemporanea de formulaciones destinadas a aplicaciones topicas para uso farmaceutico y cosmetico.
DE69831223D1 (de) Gefriergetrocknete zusammensetzung des menschlichen,morphogenen knochenproteins mp52
HUP9902415A2 (hu) Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
DE69902879D1 (de) Pflanzliches antivirales mittel
DE60036199D1 (de) Proteaseresistente flint-analoge
WO2003049692A3 (en) The use of acyl salicylates as heat shock inducers
PT100670A (pt) Formulacoes farmaceuticas topicas de oleo-em -agua ou aquosa para o tratamento de infeccoes virais

Legal Events

Date Code Title Description
ABAN Application deemed to be withdrawn (no publication fee paid)

Effective date: 20090413